Welcome to our dedicated page for PHIBRO ANIMAL HEALTH SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PHIBRO ANIMAL HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PHIBRO ANIMAL HEALTH's regulatory disclosures and financial reporting.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 1,064,608 shares of Phibro Animal Health Corporation Class A common stock, representing 5.1% of the class. They report shared voting and dispositive power over all these shares and no sole voting or dispositive power. The shares are held by entities over which Millennium Management LLC and related managers have voting control and investment discretion, with Mr. Englander serving as sole voting trustee of the managing member of Millennium Group Management LLC, while expressly not admitting beneficial ownership beyond what is required for this report.
Phibro Animal Health Corporation reported that its Board of Directors declared a quarterly cash dividend of $0.12 per share on both its Class A and Class B common stock. The dividend is payable on September 23, 2026 to stockholders of record as of the close of business on September 2, 2026.
The company describes itself as a global diversified animal health and nutrition business that works with livestock producers, farmers, veterinarians and consumers to help maintain and enhance animal health.
Bendheim Daniel M reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP reported that President and CEO Daniel M. Bendheim received a grant of 300,000 Performance Stock Units. Each unit represents a contingent right to one share of Class A Common Stock.
The performance stock units will vest, or be forfeited in full or in part, on June 30, 2031. Vesting depends on achieving specified stock price performance measured as of that date and on Bendheim’s continued employment through that time.
Phibro Animal Health Corporation appointed Daniel (Dani) Bendheim as Chief Executive Officer and President effective July 1, 2026, and approved a new employment agreement and equity award for him.
Under the agreement, he will receive an annual base salary of $850,000, a target annual cash bonus equal to 50% of base salary, and an annual grant of time-vesting restricted stock units (RSUs) targeted at approximately 50% of base salary. He will also receive an initial grant of 300,000 performance-based RSUs.
The initial RSUs vest on June 30, 2031 based on the 90-day average share price, with no vesting below $70 and full vesting at or above $100. The agreement provides severance-related COBRA subsidies, limited salary continuation on death or disability, and standard protective covenants, with accelerated RSU vesting upon certain change in control events or qualifying terminations.
Phibro Animal Health Corporation filed notices under Rule 144 reporting proposed sales of 281,600 shares of Class A Common Stock. The filing lists numerous smaller sales by BFI Co. LLC (repeated transactions of 1,760, 3,520 and other share lots on multiple dates).
The entries identify the broker Goldman Sachs & Co. LLC and show transaction dates in March–May 2026. The filing lists the sales as exchanges/private placement origins for the registered shares.
PHIBRO ANIMAL HEALTH CORP director E. Thomas Corcoran bought 10,000 shares of Class A Common Stock in an open-market purchase. The weighted average price was $31.77 per share, with trade prices ranging from $31.66 to $31.85.
After this transaction, he directly holds 41,459 shares, which includes 1,459 shares acquired through a dividend reinvestment plan sponsored by his broker.
BFI Co., LLC and Jack C. Bendheim filed an amended Schedule 13D for Phibro Animal Health, disclosing a new Rule 10b5-1 sales plan. The plan allows Goldman Sachs to sell up to 750,000 shares of Class A Common Stock through March 17, 2027, with the first possible trade date on September 16, 2026.
As of May 22, 2026, BFI beneficially owns 19,552,186 shares of common stock, equal to 48.2% of the Class A Common Stock on an as-converted basis, through 56,152 Class A shares and 19,496,034 Class B shares. If all plan shares are sold, BFI would still hold 56,152 Class A shares and 18,746,034 Class B shares.